Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

Merle P, Blanc JF, Le Malicot K, Peron JM, Bourgeois V, Bouattour M, Touchefeu Y, Vitellius C, Akouz FK, Heurgué A, Girot P, Assenat E, Nguyen-Khac E, Bronowicki JP, Viaud J, Ben Abdelghani M, Manfredi S, Edeline J, Phelip JM, TRIPLET-HCC study investigators

Open source

DOI: 10.1016/s2468-1253(26)00115-9
Published: 2026 Aug
Container: The lancet. Gastroenterology & hepatology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2468-1253-26-00115-9,
  title = {Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.},
  author = {Merle P and Blanc JF and Le Malicot K and Peron JM and Bourgeois V and Bouattour M and Touchefeu Y and Vitellius C and Akouz FK and Heurgué A and Girot P and Assenat E and Nguyen-Khac E and Bronowicki JP and Viaud J and Ben Abdelghani M and Manfredi S and Edeline J and Phelip JM and TRIPLET-HCC study investigators},
  year = {2026},
  journal = {The lancet. Gastroenterology \& hepatology},
  doi = {10.1016/s2468-1253(26)00115-9},
  url = {https://doi.org/10.1016/s2468-1253(26)00115-9}
}

RIS

TY  - JOUR
TI  - Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.
AU  - Merle P
AU  - Blanc JF
AU  - Le Malicot K
AU  - Peron JM
AU  - Bourgeois V
AU  - Bouattour M
AU  - Touchefeu Y
AU  - Vitellius C
AU  - Akouz FK
AU  - Heurgué A
AU  - Girot P
AU  - Assenat E
AU  - Nguyen-Khac E
AU  - Bronowicki JP
AU  - Viaud J
AU  - Ben Abdelghani M
AU  - Manfredi S
AU  - Edeline J
AU  - Phelip JM
AU  - TRIPLET-HCC study investigators
PY  - 2026
JO  - The lancet. Gastroenterology & hepatology
DO  - 10.1016/s2468-1253(26)00115-9
UR  - https://doi.org/10.1016/s2468-1253(26)00115-9
ER  -

APA

P, M., JF, B., K, L. M., JM, P., V, B., M, B., Y, T., C, V., FK, A., A, H., P, G., E, A., E, N., JP, B., J, V., M, B. A., S, M., J, E., JM, P., & investigators, T. S. (2026). Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.. The lancet. Gastroenterology & hepatology. https://doi.org/10.1016/s2468-1253(26)00115-9

Source records

pubmed · retrieved 2026-09-26T16:48:45.918Z
europe-pmc · retrieved 2026-09-26T16:48:45.926Z
hal · retrieved 2026-09-26T16:48:45.950Z